A Phase 4 interventional study of Levetiracetam in Epilepsy, Partial, sponsored by UCB Pharma. Completed at 29 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-19.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 7th largest by enrollment, is one of 2 that started in 2003, is one of 7 in phase 4, and was the 5th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 173 across the 18 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
29 studies in Epilepsies, Partial by UCB S.A.: none open now, none under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 29 studies in Epilepsies, Partial by UCB S.A., this one is the 8th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2003, is one of 6 in phase 4, and was the 8th registered.
UCB S.A.’s Epilepsies, Partial studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 29 in Epilepsies, Partial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures.
The optimal dose in daily clinical practice will be used.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects received open-label Levetiracetam.
Drug: Levetiracetam
* Pharmaceutical form: oral tablets * Concentration: 500 mg * Route of administration: Oral use
Also known as: Keppra
Number of Patients With Adverse Events (AEs)
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.
Time frame: From Baseline until Safety visit (two weeks after last dose; up to Week 18)
Percentage Change From Historical Baseline in Partial (Type I) Seizure Frequency Per Week Over the Treatment Period
Percentage change from baseline in partial (Type I) seizure frequency over the treatment period standardized to 1 week period. Type I Partial (focal, local) seizure frequency per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period. A negative value in percent change from historical baseline indicates a decrease in partial (type I) seizure frequency from historical baseline.
Time frame: Week 16, compared to Baseline
Percentage Change From Historical Baseline in Total (Type I+II+III) Seizure Frequency Per Week Over the Treatment Period
Percentage change from baseline in total (type I+II+III) seizure frequency over the treatment period standardized to 1 week period. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period. A negative value in percent change from historical baseline indicates a decrease in total (type I+II+III) seizure frequency from historical baseline.
Time frame: Week 16, compared to Baseline
Percentage of Participants With 50% Response in Seizure Frequency Per Week at Week 16
50% response in seizure frequency per Week is defined as \>=50% reduction in seizure frequency from Baseline. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.
Time frame: Week 16, compared to Baseline
Percentage of Participants With 100% Response in Seizure Frequency Per Week at Week 16
100% response in seizure frequency per Week is defined as 100% reduction in seizure frequency from Baseline. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.
Time frame: Week 16, compared to Baseline
Percentage of Patients With Categorized Change From Baseline in Severity of Illness
The overall change in the severity of the subject's illness, compared to the subject's condition prior to the levetiracetam intake, was assessed by the Investigator using Investigator's Global Evaluation Scale (IGS). Categories are as following: Marked improvement; Moderate improvement; Slight improvement; No change; Slight worsening; Moderate worsening; Marked worsening.
Time frame: Baseline, Week 16
Retention Rate at Week 16
Retention rate, defined as the number of subjects who were still on levetiracetam at Visit 5 (Week 16) or on the day before divided by the number of subjects in the ITT population.
Time frame: Week 16
The study started to enroll patients in November 2003 and concluded in May 2006.
| Milestone | Levetiracetam |
|---|---|
| Started | 251 |
| Completed | 218 |
| Not completed | 33 |
| Withdrew: Adverse event | 14 |
| Withdrew: Lack of efficacy | 4 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Intake of expired drug | 7 |
| Withdrew: Psychological trauma | 1 |
| Withdrew: Sponsor decision | 1 |
| Withdrew: Patient met exclusion criteria | 1 |
| Withdrew: Patient decision | 1 |
| Withdrew: Poor compliance, dilantin toxicity | 1 |
| Withdrew: Met exclusion criteria | 1 |
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment.
| Participants | Levetiracetam |
|---|---|
| Number of Patients With Adverse Events (AEs) | 184 |
Percentage change from baseline in partial (Type I) seizure frequency over the treatment period standardized to 1 week period. Type I Partial (focal, local) seizure frequency per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period. A negative value in percent change from historical baseline indicates a decrease in partial (type I) seizure frequency from historical baseline.
| percentage changes | Levetiracetam |
|---|---|
| Percentage Change From Historical Baseline in Partial (Type I) Seizure Frequency Per Week Over the Treatment Period | -48.34 (-89.96 to 6.19) |
Percentage change from baseline in total (type I+II+III) seizure frequency over the treatment period standardized to 1 week period. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period. A negative value in percent change from historical baseline indicates a decrease in total (type I+II+III) seizure frequency from historical baseline.
| percentage changes | Levetiracetam |
|---|---|
| Percentage Change From Historical Baseline in Total (Type I+II+III) Seizure Frequency Per Week Over the Treatment Period | -46.43 (-89.29 to 5.88) |
50% response in seizure frequency per Week is defined as \>=50% reduction in seizure frequency from Baseline. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.
| percentage of participants | Levetiracetam |
|---|---|
| Partial (Type I) seizures | 47.7 |
| Total (type I+II+III) seizures | 48.1 |
100% response in seizure frequency per Week is defined as 100% reduction in seizure frequency from Baseline. Types I+II+III seizure frequency (Type I: Partial (focal, local), Type II: Generalized (convulsive or non-convulsive), Type III: Unclassified) per week will be derived from the seizure count information recorded on the daily record card (e.g. date, number, type of epileptic seizures) and is defined as the number of seizures standardized to a 1 week period.
| percentage of participants | Levetiracetam |
|---|---|
| Partial (Type I) seizures | 20.2 |
| Total (type I+II+III) seizures | 20.2 |
The overall change in the severity of the subject's illness, compared to the subject's condition prior to the levetiracetam intake, was assessed by the Investigator using Investigator's Global Evaluation Scale (IGS). Categories are as following: Marked improvement; Moderate improvement; Slight improvement; No change; Slight worsening; Moderate worsening; Marked worsening.
| percentage of participants | Levetiracetam |
|---|---|
| Marked improvement | 34.1 |
| Moderate improvement | 25.3 |
| Slight improvement | 16.5 |
| No change | 17.7 |
| Slight worsening | 3.2 |
| Moderate worsening | 2.8 |
| Marked worsening | 0.4 |
Retention rate, defined as the number of subjects who were still on levetiracetam at Visit 5 (Week 16) or on the day before divided by the number of subjects in the ITT population.
| percentage of participants | Levetiracetam |
|---|---|
| Retention Rate at Week 16 | 85.3 |
Collected over Adverse events were collected from Visit 2 (week 2) until Safety Visit (up to 2 weeks after the last dose, up to 16 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levetiracetam | — | 15/251 (6%) | 136/251 (54.2%) |
| Event | Levetiracetam |
|---|---|
| ConvulsionNervous system disorders | 4/251 |
| DizzinessNervous system disorders | 2/251 |
| Grand mal convulsionNervous system disorders | 2/251 |
| BicytopeniaBlood and lymphatic system disorders | 1/251 |
| Adverse drug reactionGeneral disorders | 1/251 |
| Dengue feverInfections and infestations | 1/251 |
| Thermal burnInjury, poisoning and procedural complications | 1/251 |
| Coordination abnormalNervous system disorders | 1/251 |
| Depressed level of consciousnessNervous system disorders | 1/251 |
| LethargyNervous system disorders | 1/251 |
| Event | Levetiracetam |
|---|---|
| SomnolenceNervous system disorders | 75/251 |
| DizzinessNervous system disorders | 36/251 |
| HeadacheNervous system disorders | 16/251 |
| FatigueGeneral disorders | 15/251 |
| SedationNervous system disorders | 15/251 |
| NauseaGastrointestinal disorders | 14/251 |
Baseline characteristics refer to the Intend-to-treat (ITT) Set.
| Age, Categorical(Participants) | Levetiracetam |
|---|---|
| <=18 years | 10 |
| Between 18 and 65 years | 240 |
| >=65 years | 1 |
| Age, Continuous(years) | Levetiracetam |
|---|---|
| Mean | 34.42 ± 11.21 |
| Sex: Female, Male(Participants) | Levetiracetam |
|---|---|
| Female | 137 |
| Male | 114 |
Ran from Nov 2003 to primary completion in Dec 2006, 36 months.
Results were first posted in Aug 2020, 13 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam